Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)

Inclusion Criteria: * Patient with LOPD or IOPD who has previously completed Study EFC14028, LTS13769, or ACT14132 in France, and reimbursement for avalglucosidase alfa is not yet granted in France. * The patient and/or their parent/legal guardian is willing and able to provide signed informed consent, and the patient, if \<18 years of age, is willing to provide assent if deemed able to do so. * The patient (and patient's legal guardian if patient is \<18 years of age) must have the ability to comply with the clinical protocol. * The patient, if female and of childbearing potential, must have a negative pregnancy test result \[urine beta-human chorionic gonadotropin (β-HCG)\] at enrollment. * Sexually active female patients of childbearing potential and male patients are required to practice true abstinence in line with their preferred and usual lifestyle or to use 2 acceptable effective methods of contraception. Exclusion Criteria: * Patient with life-threatening hypersensitivity (anaphylactic reaction) to one of avalglucosidase alfa's excipients. * Patient who permanently discontinued avalglucosidase alfa in a previous clinical study * Pregnant or breastfeeding female patient * The patient is concurrently participating in another clinical study of investigational treatment. * The patient, in opinion of the Investigator, is unable to comply with the requirements of the study. * The patient has clinically significant organic disease (with the exception of symptoms relating…